000			05602nam a2200445 i 4500
999			_c382784 _d382784
001			382784
003			ES-MaUEC
005			20230102122014.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			220410s2022 sz | o |||| 0|eng d
020			_a9783030874803
024	7		_a10.1007/978-3-030-87480-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQP364.5 _b2022 EB
245	0	0	_aGlutamate and Neuropsychiatric Disorders : _bCurrent and Emerging Treatments _cedited by Zoran M. Pavlovic
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XXXV, 600 páginas) _b43 ilustraciones, 40 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aTreatments Against Glutamatergic Excitotoxicity in Ischemic Stroke -- Definitions and Concepts of Stress -- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response -- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders -- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments -- Glutamate in Migraine Neurobiology and Treatment -- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia -- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder -- CNS Glutamate in Impulsive Aggression -- Glutamatergic Treatments for Parkinsons' Disease -- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression -- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease -- Modulation of Glutamate for Chronic Pain Management -- Pharmacological Role of Glutamate Transporters in Substance Use Disorders -- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments -- The Role of Glutamate Dysregulation in the Etiology of ADHD -- Glutamate, Glutamatergic Drugs and Schizophrenia -- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy -- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies -- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders.
520			_aThis volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development. In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer's Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines. The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence. Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9147745 _aNeurotransmisores
650		7	_2embne _9155047 _aÁcido glutámico
700	1		_aPavlovic, Zoran M. _eeditor literario
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783030874797
776	0	8	_iPrinted edition: _z9783030874810
776	0	8	_iPrinted edition: _z9783030874827
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-87480-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eb _zSI